{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33"],"submitter":["Carle C"],"pubmed_abstract":["<h4>Background</h4>The early COVID-19 literature suggested that people with cancer may be more likely to be infected with SARS-CoV-2 or develop COVID-19 than people without cancer, due to increased health services contact and/or immunocompromise. While some studies were criticised due to small patient numbers and methodological limitations, they created or reinforced concerns of clinicians and people with cancer. These risks are also important in COVID-19 vaccine prioritisation decisions. We performed a systematic review to critically assess and summarise the early literature.<h4>Methods and findings</h4>We conducted a systematic search of Medline/Embase/BioRxiv/MedRxiv/SSRN databases including peer-reviewed journal articles, letters/commentaries, and non-peer-reviewed pre-print articles f"],"journal":["Journal of cancer policy"],"pagination":["100338"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9167683"],"repository":["biostudies-literature"],"pubmed_title":["The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence."],"pmcid":["PMC9167683"],"pubmed_authors":["Ginsburg O","Sullivan R","Canfell K","Yap S","Egger S","Hui H","Peacock SJ","Carle C","Deandrea S","Caruana M","Chan KKW","Hanna TP","Hughes S","Campbell D","Onyeka TC","Aggarwal A","Bray F","Freeman V","IJzerman MJ","O'Connell DL","Steinberg J","Soerjomataram I"],"additional_accession":[]},"is_claimable":false,"name":"The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence.","description":"<h4>Background</h4>The early COVID-19 literature suggested that people with cancer may be more likely to be infected with SARS-CoV-2 or develop COVID-19 than people without cancer, due to increased health services contact and/or immunocompromise. While some studies were criticised due to small patient numbers and methodological limitations, they created or reinforced concerns of clinicians and people with cancer. These risks are also important in COVID-19 vaccine prioritisation decisions. We performed a systematic review to critically assess and summarise the early literature.<h4>Methods and findings</h4>We conducted a systematic search of Medline/Embase/BioRxiv/MedRxiv/SSRN databases including peer-reviewed journal articles, letters/commentaries, and non-peer-reviewed pre-print articles f","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-05-31T23:34:55.648Z","creation":"2025-05-31T23:34:55.648Z"},"accession":"S-EPMC9167683","cross_references":{"pubmed":["35671919"],"doi":["10.1016/j.jcpo.2022.100338"]}}